PE20140182A1 - Proceso para la preparacion de compuestos heteroarilos inhibidores de pan-cdk e intermediarios de la preparacion - Google Patents

Proceso para la preparacion de compuestos heteroarilos inhibidores de pan-cdk e intermediarios de la preparacion

Info

Publication number
PE20140182A1
PE20140182A1 PE2013000617A PE2013000617A PE20140182A1 PE 20140182 A1 PE20140182 A1 PE 20140182A1 PE 2013000617 A PE2013000617 A PE 2013000617A PE 2013000617 A PE2013000617 A PE 2013000617A PE 20140182 A1 PE20140182 A1 PE 20140182A1
Authority
PE
Peru
Prior art keywords
formula
nitrophenyl
give
preparation
sulfoximine
Prior art date
Application number
PE2013000617A
Other languages
English (en)
Inventor
Joachim Kruger
Jorg Gries
Kai Lovis
Jorma Hassfeld
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44677881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140182(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of PE20140182A1 publication Critical patent/PE20140182A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C07C381/10Compounds containing sulfur atoms doubly-bound to nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)

Abstract

REFERIDA A UN PROCESO DE PREPARACION DE UN COMPUESTO DE FORMULA (I), DONDE R4 ES ALQUILO C1-C6 O UN ANILLO CICLOALQUILO C3-C7, QUE COMPRENDE: a) ALQUILACION MEDIANTE X-R4 DE 4-NITROTIOFENOL EN PRESENCIA DE CARBONATO DE POTASIO EN N-METIL-PIRROLIDINONA PARA DAR UN NITROFENIL-SULFURO DE FORMULA (I-1), DONDE X ES Br, Cl, I, O-SO2-CH3 U O-SO2-(4-METILFENILO), b) AMINACION OXIDATIVA DE (I-1) PARA DAR UNA NITROFENIL-SULFILIMINA DE FORMULA (I-10), c) OXIDACION DE (I-10) PARA DAR UNA NITROFENIL-SULFOXIMINA PROTEGIDA CON TRIFLUOROACETATO DE FORMULA (I-3) Y DESPROTECCION PARA DAR UNA NITROFENIL-SULFOXIMINA DE FORMULA (I-11), d) SEPARACION DEL RACEMATO DE (I-11) CON ACIDO (+)-DI-O-P-TOLUIL-D-TARTARICO DONDE EL ENANTIOMERO R DE LA NITROFENIL-SULFOXIMINA SE SEPARA DE LAS SALES Y EL GRUPO PROTECTOR TRIFLUOROACETATO SE INSERTA NUEVAMENTE PARA FORMAR EL ENANTIOMERO R DE LA NITROFENIL-SULFOXIMINA PROTEGIDA CON TRIFLUOROACETATO DE FORMULA (I-3-R), e) HIDROGENACION DE (I-3-R) PARA DAR LAS ANILINO-SULFOXIMINAS PROTEGIDAS CON TRIFLUOROACETATO DE FORMULA (I-4-R) CON UN CATALIZADOR DE PALADIO DOPADO CON HIERRO, f) PREPARACION DE (2R,3R)-3-(BENCILOXI)BUTAN-2-OL (I-5-A) EN UN PROCESO EN DOS ETAPAS POR MEDIO DE (4R,5R)-4,5-DIMETIL-2-FENIL-1,3-DIOXOLANO, DONDE LA PRIMERA ETAPA SE LLEVA A CABO CON P-TOLUENSULFONATO DE PIRIDINIO EN TOLUENO Y LUEGO OCURRE UNA REDUCCION CON HIDRURO DE IISOBUTILALUMINIO EN TOLUENO, ENTRE OTROS PASOS
PE2013000617A 2010-09-23 2011-09-20 Proceso para la preparacion de compuestos heteroarilos inhibidores de pan-cdk e intermediarios de la preparacion PE20140182A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102010046720A DE102010046720A1 (de) 2010-09-23 2010-09-23 Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung

Publications (1)

Publication Number Publication Date
PE20140182A1 true PE20140182A1 (es) 2014-02-14

Family

ID=44677881

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000617A PE20140182A1 (es) 2010-09-23 2011-09-20 Proceso para la preparacion de compuestos heteroarilos inhibidores de pan-cdk e intermediarios de la preparacion

Country Status (32)

Country Link
US (1) US9359306B2 (es)
EP (1) EP2619186A1 (es)
JP (1) JP5969993B2 (es)
KR (1) KR20130109145A (es)
CN (1) CN103119026B (es)
AP (1) AP2013006816A0 (es)
AR (1) AR083171A1 (es)
AU (1) AU2011304365B2 (es)
BR (1) BR112013006720A2 (es)
CA (1) CA2811807A1 (es)
CL (1) CL2013000797A1 (es)
CO (1) CO6690779A2 (es)
CR (1) CR20130138A (es)
CU (2) CU20130044A7 (es)
DE (1) DE102010046720A1 (es)
DO (1) DOP2013000063A (es)
EC (1) ECSP13012520A (es)
GT (1) GT201300078A (es)
HK (1) HK1185615A1 (es)
IL (1) IL225352A0 (es)
MX (1) MX2013003338A (es)
MY (1) MY160625A (es)
NZ (1) NZ608448A (es)
PE (1) PE20140182A1 (es)
RU (1) RU2585621C2 (es)
SA (1) SA111320775B1 (es)
SG (1) SG188967A1 (es)
TW (1) TWI530488B (es)
UA (1) UA110626C2 (es)
UY (1) UY33624A (es)
WO (1) WO2012038411A1 (es)
ZA (1) ZA201301799B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
WO2014173815A1 (en) * 2013-04-23 2014-10-30 Bayer Pharma Aktiengesellschaft Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours
AR113344A1 (es) 2017-10-05 2020-04-22 Innovative Molecules Gmbh Enantiómeros de una serie de compuestos antivirales
AU2019221019B2 (en) 2018-02-13 2024-05-02 Bayer Ag Use of 5-Fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large B-cell lymphoma

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA964426B (en) * 1995-06-05 1997-03-06 Rhone Poulenc Agrochimie Pesticidal sulfur compounds
EP1291336A3 (en) 2001-09-05 2003-10-08 Solvias AG Preparation of optically active alpha-hydroxyethers
DE10349423A1 (de) * 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102005062742A1 (de) * 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
EP2022785A1 (en) * 2007-06-20 2009-02-11 Bayer Schering Pharma Aktiengesellschaft Alkynylpyrimidines as Tie2 kinase inhibitors
EP2179991A1 (de) 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
ECSP13012520A (es) 2013-05-31
ZA201301799B (en) 2014-05-28
DE102010046720A1 (de) 2012-03-29
AR083171A1 (es) 2013-02-06
UA110626C2 (uk) 2016-01-25
CO6690779A2 (es) 2013-06-17
SA111320775B1 (ar) 2015-02-03
SG188967A1 (en) 2013-05-31
IL225352A0 (en) 2013-06-27
CN103119026A (zh) 2013-05-22
TW201215596A (en) 2012-04-16
GT201300078A (es) 2014-11-26
CR20130138A (es) 2013-05-15
CU20130044A7 (es) 2013-07-31
MY160625A (en) 2017-03-15
WO2012038411A1 (de) 2012-03-29
RU2013118432A (ru) 2014-10-27
KR20130109145A (ko) 2013-10-07
RU2585621C2 (ru) 2016-05-27
TWI530488B (zh) 2016-04-21
EP2619186A1 (de) 2013-07-31
JP5969993B2 (ja) 2016-08-17
DOP2013000063A (es) 2013-04-30
BR112013006720A2 (pt) 2016-06-14
US9359306B2 (en) 2016-06-07
AU2011304365B2 (en) 2015-02-05
AU2011304365A1 (en) 2013-04-11
MX2013003338A (es) 2013-06-24
NZ608448A (en) 2014-10-31
HK1185615A1 (en) 2014-02-21
US20130245261A1 (en) 2013-09-19
AP2013006816A0 (en) 2013-04-30
JP2013542189A (ja) 2013-11-21
CN103119026B (zh) 2015-08-19
CA2811807A1 (en) 2012-03-29
CL2013000797A1 (es) 2013-09-13
CU20150165A7 (es) 2016-05-30
UY33624A (es) 2012-04-30

Similar Documents

Publication Publication Date Title
PE20140182A1 (es) Proceso para la preparacion de compuestos heteroarilos inhibidores de pan-cdk e intermediarios de la preparacion
GT200900183A (es) Derivados de isoquinolina e isoquinolinona sustituidos con cicloalquilamina
PE20142456A1 (es) COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks
UA109199C2 (uk) Дигідропіридинові сполуки, корисні для лікування від залежності, викликаної агентами, що стимулюють вироблення дофаміну
ECSP11011008A (es) Proceso para la preparación de derivados de l-alanina protegidos
AR081333A1 (es) Metodo para preparar derivados de cicloalquilcarboxamidoindol, en particular (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida, compuestos intermediarios de dicha sintesis y metodo para prepararlos.
CL2011001586A1 (es) Metodo que comprende una composicion que contiene sulfoximida de 6-haloalquilpiridin-3-il-alquilo n-sustituida; composicion comprendiendo una mezcla estereoisomera de dicha sulfoximida en una formulacion farmaceutica acuosa.
SV2009003316A (es) Nuevos derivados de isoquinolina e isoquinolinona sustituidos
UA108378C2 (uk) Спосіб одержання плеуромутилінів
ECSP088854A (es) Moduladores bencimidazolicos de vr1
CL2009002201A1 (es) Procedimiento de sintesis de ivabradina por aminacion reductiva y posterior resolucion optica; y uno de los compuestos intermediarios considerados.
ES2657549T3 (es) Piridopirazinas sustituidas como nuevos inhibidores de SYK
BR112013020912A2 (pt) processo para a remoção de um composto orgânico de uma solução aquosa e mistura de reação compreendendo uma solução aquosa e uma solução orgânica hidrófoba
AR109669A1 (es) Proceso para preparar 2-exo-(2-metilbenciloxi)-1-metil-4-isopropil-7-oxabiciclo[2.2.1]heptano
CR20160202A (es) Procedimiento de preparación de una sal de tipo camsilato
UY31388A1 (es) Método para la producción de 2´-desoxi-5-azacitidina (decitabina)
UY36651A (es) Compuestos antiestrogénicos
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen
MA35886B1 (fr) Dérivés de benzylsulfanilamide utilisés comme inhibiteurs -2 mogat
WO2013093931A3 (en) Novel prodrugs of phenolic drugs
MA37501B1 (fr) Composés de pyrazole utilisés en tant qu'inhibiteurs de sglt1
PE20091359A1 (es) Proceso de preparacion de compuestos organicos intermediarios de inhibidores de renina
ES2613698T3 (es) Combinación, kit y método de reducción de la presión intraocular
AR081034A1 (es) Derivados de n-heteroaril tetrahidro-isoquinolina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades del sistema nervioso central
EA201300249A1 (ru) Способ обогащения соли аминосоединения

Legal Events

Date Code Title Description
FD Application declared void or lapsed